Medicamen Biotech Balance Sheet
- Market cap
- ₹413 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹219.46 – ₹411.48
As of FY25, Medicamen Biotech had total assets of ₹269 crore and borrowings of ₹49.61 crore, against shareholders' equity of ₹306 crore — a debt-to-equity ratio of 0.35.
Medicamen Biotech balance sheet
As at each financial year end, newest first. H1 = half-year.
| Item | FY25 |
|---|---|
| Equity capital | 120 |
| Reserves | 186 |
| Borrowings | 49.61 |
| Other liabilities | 33.07 |
| Total liabilities | 269 |
| Fixed assets | 145 |
| Capital work in progress | 45 |
| Investments | 62.01 |
| Other assets | 62.01 |
| Total assets | 269 |
Balance sheet ratios
- Debt to equity
- 0.35
- Book value per share
- ₹106.95
Source: Company filings (consolidated), in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Medicamen Biotech balance sheet — frequently asked questions
What is the total debt of Medicamen Biotech?
Medicamen Biotech reported borrowings of ₹49.61 crore as of FY25.
What is Medicamen Biotech's debt-to-equity ratio?
Based on the FY25 balance sheet, Medicamen Biotech's debt-to-equity ratio is 0.35 — borrowings of ₹49.61 crore against equity capital and reserves of ₹306 crore.
What are Medicamen Biotech's total assets?
Medicamen Biotech's total assets were ₹269 crore as of FY25, including fixed assets of ₹145 crore and investments of ₹62.01 crore.
What is the book value per share of Medicamen Biotech?
The book value per share of Medicamen Biotech is ₹106.95, based on the latest reported balance sheet.
Same Data For Peers
Trade Medicamen Biotech With ATS
Track MEDICAMEQ live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.